Prion diseases or transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative diseases, clinically characterised by cognitive decline, paralleled by severe damage to the central nervous system. Prion diseases have attracted a broad interest because of their unique mechanisms of replication and propagation; however, the underlying pathogenic mechanisms are still highly speculative. In this review, current knowledge about the pathogenesis of prion diseases in the CNS will be highlighted and the most revealing animal models will be discussed, with future perspectives to address immediate questions about the pathogenesis.
hypothesis 1, 2 ; (ii) determine the molecular basis of the species barrier [3] [4] [5] [6] ; or (iii) characterise the entry route and neuro-invasion of prions [7] [8] [9] .
The pathogenesis of prion diseases
Important supporting evidence for the protein-only hypothesis was the generation of mice with targeted disruption of the Prnp gene 1, 10, 11 . Although it was proposed that the ubiquitously expressed neuronal protein PrP C may have crucial functions in development and neuronal function 12 , homozygous PrP knock-out mice generated by Büeler et al 1 and Manson et al 10 showed no overt developmental or behavioural abnormalities, but only subtle sleep defects 13 and electrophysiological abnormalities suggesting that PrP may play a role in synaptic plasticity 14 , which could be reverted by re-introduction of a transgene encoding human PrP 15 . The Prnp -/-mice generated by Sakaguchi et al 11 instead presented with progressive ataxia from 70 weeks of age, caused by extensive loss of cerebellar Purkinje cells. Only recently, has it been discovered that this phenotype was not caused by the ablation of PrP function but by the activation of doppel, a gene 16 kb downstream of the Prnp locus 16 . Re-introduction of mouse PrP transgenes in Prnp null mice restored their susceptibility to mouse prions in a dose-dependent fashion 17 , confirming an inverse relationship between the steady-state level of host PrP C and the incubation time 18 . Instead, introducing a Syrian hamster Prnp gene into PrP null mice rendered these animals extremely susceptible to hamster prions, but made them almost resistant to mouse prions 19 . The essential role of PrP C itself in prion propagation was confirmed when Prnp knock-out mice were intracerebrally challenged with prions 19, 20 . All three lines of these null mice not only lacked any clinical signs of scrapie disease but also showed unaffected brains, which did not harbour any infectivity or protease resistant PrP; thus, ablation of PrP C abolished prion replication and propagation 10, 11, 19, 21 At this point, it could be argued that PrP knockout mice were not affected because ablation of the normal host PrP removed the substrate for further conversion into PrP Sc . Hence, the role of PrP Sc -mediated neurotoxicity had to be addressed differently. To achieve a sustained delivery of prions to the 'prion-replication defective' brains, we introduced neurografts expressing high PrP levels and inoculated them with prions 22 . These neurografts not only replicated and accumulated PrP Sc and prion infectivity, but also delivered substantial amounts of prions to the host brain, notably without eliciting any clinical disease or neuropathological sign of spongiform encephalopathy. Hence, PrP C is an indispensable substrate to elicit disease in the brain, and deposition of prions alone does not support neurodegeneration. These findings have kindled a series of further questions on the mechanisms of brain damage in TSEs. First, it is still obscure as to what eventually triggers neurodegeneration and what the targets in the CNS are. Second, how can low-level prion persistence in a subclinically affected subject be explained?
Mechanisms of cell death in prion disease
A large number of studies has been undertaken to analyse the role of PrP in neurodegeneration. Of particular interest are the function of PrP C in neuroprotection, and the mechanism of cell death induced by, or during, the conformational conversion from PrP C into PrP Sc . Despite much progress in the elucidation of the molecular pathways involved in the activation of cell death cascades, the mechanism of prion-induced cell death still remains obscure. Apoptotic cell death has been described in various cell culture systems 23, 24 and in vivo 25, 26 , and several hypotheses have been put forward to explain the neurotoxicity that leads to apoptosis, among them oxidative stress 27 , microgliamediated damage 28 , and even the involvement of copper 29 leading to increased levels of caspase 3, Fas activation, and up-regulation of the transcription factor c-jun 30 . Recently, the role of PrP C as a protein with anti-apoptotic function has been highlighted 31 . It could be speculated that alteration of PrP function (e.g. by interaction with, or sequestration by, PrP Sc ) also affects a homoor heterodimerization of Bcl-2, or their expression, resulting in neuronal apoptosis. It has also been argued that binding and sequestration of ubiquitous members of the Bcl-2 family should also trigger cell death in non-neuronal cells. Since these show little or no alteration, further brain-specific factors, other than the Bcl-2 family members, may be more relevant 32 . However, while loss of neurons can hardly be compensated, replacement of non-neuronal cells may happen unnoticed, particularly in the lymphoreticular compartment.
As will be discussed in detail below, overall loss of neurons may not be the most relevant event in prion disease. Patients may even be symptomatic through loss of neuronal connectivity and neurite degeneration, causing cell death only at a later stage.
Low level persistence
Mice harbouring only one wild-type allele of Prnp show partial resistance to scrapie infection, reflected by almost doubled incubation times [Plate XI(A)]. While onset of symptoms and rate of disease progression apparently correlate with steady-state levels of host-PrP C , the disease severity did not as mice heterozygous for Prnp showed a very benign course of disease. How can low-level persistence be explained in the framework of the protein-only hypothesis? Under typical experimental conditions, prions are inoculated into a suitable host, resulting in scrapie disease after an incubation time that is inversely correlated with the inoculated amount of infectivity. Typical applications are: (i) bioassays to determine the infectivity titre of a given inoculum by comparing it to a standard curve; or (ii) to investigate the influence of a specific treatment or a genetic defect (introduced by transgenesis) on the susceptibility to scrapie prions. However, all these experiments strongly rely on a reproducible response to a given dose of infectivity. This is the case, for example, for prion inocula derived from the Chandler strain (Rocky Mountain Laboratory, RML), transmitted into appropriate mouse lines. However, there are also reasons to believe that exposure to prions does not always result in clinical disease. As outlined above, Prnp o/o mice, which do not replicate prions, may nevertheless harbour low-level infectivity but never succumb to disease. These traces of prion infectivity were either ascribed to a low-level persistence of inoculum 2 or were experimentally forced by an infected neurograft [Plate XI(B)] 22 . Further examples, in which high-level prion titres accumulate without development of clinical signs of TSE, are immunodeficient mice, which have been peripherally challenged with prions 9, 33 . In contrast to the above examples, in which a prion species barrier did not prevent replication, the exposure of humans to BSE involves crossing such a species barrier. Although a broad population in the UK has been exposed to BSE prions, only a relatively small fraction actually has developed the new variant of Creutzfeldt-Jakob disease (vCJD). This discrepancy could be explained by persistence of prions in lymphoreticular organs, which invariably takes place and is being used to diagnose preclinical vCJD 34 ; but the fact that there is also low-level, subclinical persistence of the BSE prions in the CNS cannot be excluded. This assumption is supported by one transmission study of BSE into mice, which then harboured infectivity that could be further passaged but did not always accumulate PrP Sc in their brains 35 . Similarly, mice inoculated with hamster prions accumulated prion infectivity in their brains and spleens, which was not ascribed to residual infectivity as transmission into Prnp knock-out mice did not yield any infectivity 36 . There is, however, an important parallel to the transmission of BSE to humans. In both settings, the incoming prions retained their strain specific attributes. The banding pattern of BSE and vCJD brains is indistinguishable in immunoblot analysis of brain extracts, indicating a preservation of the BSE strain following transmission to humans 37 , and infectivity found in wild-type mice that had received hamster prions retains the property of hamster, and not of mouse, prions as it elicited scrapie in hamsters but not in mice [Plate XI(C)] 36, 38, 39 . The replication of hamster prions in a mouse host (or of prions with a BSE pattern in human brains) is probably best explained 40 by an 'over-rule mechanism' in which the incoming prions strain passes its conformation over to the host PrP while converting it to PrP Sc . This finding has important implications for farm-animal husbandry and the entry of animals into the food chain, if ingestion of BSE-contaminated food causes such animals to become subclinical carriers of BSE prions 
Clinical target areas: key to the understanding of scrapie neuropathogenesis?
The importance of the selective vulnerability and injury of specific brain regions was first highlighted by Kimberlin and Walker 42, 43 who proposed the clinical target areas in scrapie disease. Having studied neuroinvasion and spread within the CNS, they suggested that clinical signs evolve when neuronal damage, caused by whichever mechanism, exceeded a certain threshold 43 . After intracereberal inoculation, replication and accumulation of PrP Sc and infectivity occurs at a nearly constant exponential rate until clinical disease develops. Following intraperitoneal inoculation, the thoracic spinal cord was the first region of the CNS to be colonised by prions, followed by a bi-directional spread towards lumbar and cervical spinal cord, respectively 42 . The disease interval to first detection of infectivity in the thoracic cord after intraperitoneal inoculation was shorter than the interval following intracerebral inoculation. Given the evidence for intra-axonal spread of prions within the CNS 22, [44] [45] [46] , the shorter disease interval following thoracic prion colonisation could be explained by a more speedy transport towards the clinical target areas, which may be located in brain stem nuclei. Kimberlin and Walker suggested that the differences may reflect the relative efficiency of the neural pathways by which infectivity spreads from different sites of entry in the brain to the postulated clinical target areas 42 . However, there are not many experimental approaches to strengthen this point. A possible approach to identify such target areas could be the injection of prions into these assumed target areas, or into a part of the CNS that is closely connected. One possible method of limiting the spread of prions following injection would be stereotaxic implantation of metal or plastic spheres which had been coated with prion infectivity. The drawback of this approach would be the relatively limited accuracy and, whilst it would be possible to target a specific anatomical area, it would be limited to non-vital neuro-anatomical structures which are well circumscribed. Targeting a functional system, such as cholinergic or GABA-ergic neuronal circuits, would require a transgenic approach. Transgenic mice expressing PrP specifically in functional, physiologically relevant systems would be a feasible, though laborious, option, requiring dozens of transgenic mouse lines, each one expressing PrP under the control of a different promoter [Plate XII(A)]. This approach also suffers from variation in expression levels, due to integration effects and variability in copy number.
An elegant solution to this problem can be achieved by the use of inducible mouse mutants. One mouse line expressing the enzyme Cre recombinase under a cell-or region-specific promoter is crossed to another mouse line The advantage over the classic transgenic approach is a better control of expression levels and a well-defined pattern of expression, but it has the drawback of being dependent on Cre-transgenic mouse lines. The ideal readout of such an experiment would be a significant difference in incubation times between different mouse lines expressing PrP in distinct neuronal circuits or anatomical regions. 47 , crossed with suitable Cretransgenic mice will selectively lose PrP in specific brain regions or cell types. Obviously, the readout would be a reduction of clinical signs and, perhaps, a milder disease progression.
Experimental verification of the functionality of this strategy would be the generation of transgenic mice, which express antisense RNA in neurons or in specific neuronal subsets [Plate XII(E)]. Inducible systems, such as the Tet-on/Tet-off system which uses a transactivator protein (tTA), composed of the repressor of the tetracycline operon (tetR) from Escherichia coli (Tn 10) and the activating domain of the herpes simplex virus protein 16 (HSV-VP16) 49 , or the Gal4/Lac system 50 would allow for a controlled down-regulation of Prnp mRNA and might prove the feasibility and efficacy of therapeutic interventions aiming at a reduction of PrP C .
Rationale for therapies aiming at a reduction of PrP expression
Cellular PrP is undisputedly the substrate for PrP Sc -mediated conformational conversion, and Prnp knock-out mice lacking this substrate are resistant to scrapie and do not propagate prions. Given the additional fact that ablation of PrP in the developed brain does not cause any negative adverse effect 47, 51 , therapeutic approaches aiming at a reduction of PrP C expression appear to be straightforward, although currently not easy to achieve 40 . However, whether removal of the substrate actually rescues the brain from a progressive clinical disease has yet to be clarified. Several experimental approaches are conceivable, all of them involving transgenic mice. Mice expressing PrP under control of a tTA-responsive promoter have been generated and have shown that down-regulation of PrP expression in the developed CNS is innocuous and that down-regulation of PrP expression prolongs the life span of infected animals, but data aiming at reduction of PrP expression are lacking.
Yet another strategy is the (irreversible) Cre-mediated inactivation of PrP. To achieve a temporally controlled reduction of PrP, an inducible Cre transgenic mouse line would be the method of choice for performing this experiment. The readout will be most useful for the understanding of scrapie pathogenesis. Of equal importance, it will indicate whether therapeutic approaches aiming at PrP suppression are a rational proposition.
